Testing effectiveness (Phase 2)Ended earlyNCT02203513
What this trial is testing
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
Who this might be right for
Ovarian CancerBreast CancerProstate Cancer
National Cancer Institute (NCI) 111